Reforgene named a potential unicorn enterprise in China
On June 20, 2023, at the China (Suzhou) Unicorn Enterprise Conference, Great Wall Strategy Consulting released the "China Potential Unicorn Enterprise Research Report 2023". With its rapid development and technological innovation capability in the gene editing medicine field, Reforgene was listed among China's potential unicorn enterprises, gaining industry and social recognition. This is another honor for Reforgene following its selection as a 2022 Guangzhou Future Unicorn innovative enterprise, confirming the company's continuously growing technological strength.
The new round of global technological revolution and industrial transformation is accelerating, and technological innovation has become a revolutionary force driving social progress. Potential unicorn enterprises bear the important mission of the technological revolution and industrial transformation, are typical representatives of technology backbone enterprises, and play an important role in leading technological innovation, opening up new fields and new tracks, and shaping new development drivers and advantages.
In 2022, China's potential unicorn enterprises were distributed across 54 cities. Among them, Beijing had 138, Shanghai 118, Suzhou 75 and Shenzhen 54, with the four cities accounting for 59% of the national total; Guangzhou, Hangzhou and Nanjing each had more than 25 potential unicorn enterprises. It is worth noting that 13 cities, including Changzhou, Dongying, Guang'an, Mianyang, Yichun and Zhenjiang, saw their first potential unicorn enterprises. More than 90% of potential unicorn enterprises were distributed in the four city clusters of Beijing-Tianjin-Hebei, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and Chengdu-Chongqing, totaling 598; more than 60% were distributed in 31 national high-tech zones, totaling 431.
Frontier technology potential unicorn enterprises accounted for more than 70%. In 2022, a total of 477 potential unicorn enterprises belonged to frontier technology fields, with more than 20 enterprises in each of seven tracks including integrated circuits, innovative drugs and artificial intelligence. China's potential unicorn enterprises held 17,670 valid patents, of which 6,590 were valid invention patents. A total of 114 potential unicorn enterprises held 446 PCT patent applications, with enterprises in the innovative drug track performing particularly well.
In 2022, a total of 48 potential unicorns advanced to unicorn status or successfully listed. In 2022, 374 potential enterprises received new financing totaling USD 15.26 billion, with nearly 80% of integrated circuit track enterprises receiving new financing in 2022. In 2022, 38 enterprises grew into unicorn enterprises, and 10 enterprises successfully listed on domestic and international capital markets, of which 7 listed on the STAR Market of the Shanghai Stock Exchange, 2 on the Hong Kong Stock Exchange and 1 on NASDAQ.
Great Wall Strategy Consulting is the earliest think tank institution in China to research and release the "Unicorn" list, having released the China Unicorn Enterprise list and research reports for seven consecutive years since 2016, and the China Potential Unicorn Enterprise list and research reports for four consecutive years since 2020.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.